Protect effects of perilla seed extract and its active ingredient luteolin against inflammatory bowel disease.
Protect Effects of Perilla Seed Extract and Its Active Ingredient Luteolin Against Inflammatory Bowel Disease Model via the PI3K/AKT Signal Pathway In Vivo and In Vitro.
AI Summary
Key Findings
Abstract
The purpose of this study was to investigate the anti-inflammatory effects of Perilla Seed Extract (PSE) and its active ingredient on Inflammatory Bowel Disease (IBD) in vitro and in vivo. Thirty-two C57/BL mice were randomly divided into four groups (= 8): control group (CON), PBS group, LPS group (LPS 3.5 mg/kg given intraperitoneally [ip] on day 7 of the study only), and PSE group (100 mg/kg orally daily + LPS ip at 3.5 mg/kg on day 7). Mice were euthanized 24 h after LPS administration. MODE-K cells were divided into five groups: control group (CON), LPS group (50μg/mL LPS for 2 h), and PSE group (low dose, 25μg/mL PSE + LPS; middle dose, 50μg/mL PSE + LPS; high dose, 100μg/mL PSE + LPS). In vivo, compared with the CON group, LPS revealed a significant decrease in the villus length-to-crypt depth ratio (
Affiliation
Jin Zhang
External References
- PubMed ID:
- 40332054
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.